帕洛诺司琼预防老年肺癌化疗后恶心呕吐的疗效观察  

Observation on the efficacy ofpalonosetron in preventing chemotherapy induced nausea and vomiting on lung cancer in elderly patients

作　　者：沈立[1] 沈红[1] 杜强[1] 蔡健康[1] 

机构地区：[1]南京医科大学第二附属医院呼吸科,江苏南京210011

出　　处：《今日健康》2014年第4期33-34,共2页

摘　　要：目的评价帕洛诺司琼联合地塞米松预防老年肺癌含铂方案化疗所致恶心、呕吐的有效性和安全性。方法将用含铂化疗方案的71例老年肺癌患者随机分为观察组35例，对照组36例，观察组于化疗前30min缓慢静脉注射帕洛诺司琼0．25mg，对照组静脉滴注托烷司琼5mg，2组均于第1-4天化疗前分别静脉滴注地塞米松5mg，观察患者化疗引起的急性期、延迟期及全期呕吐的完全缓解率（CRR）及无呕吐发作百分率。结果2组急性期、延迟期CRR比较差异无统计学意义（P〉0．05），但观察组全期CRR高于对照组（P〈O．05）；2组急性期无呕吐发作率比较差异无统计学意义（P〉O．05），但在延迟期及全期差异有统计学意义（P〈O．05）。2组不良反应主要为头痛、便秘、眩晕及腹部不适等，症状轻微，患者耐受性好。结论帕洛诺司琼联合地塞米松能有效地预防高致吐性化疗药所致急性期、延迟期呕吐反应，对于延迟期呕吐反应其疗效优于托炕司琼，且安全性高。Objective To observe and assess the efficacy and safety of palonosetron plus dexamethasone in preventing Pt.containing chemotherapy induced nausea and vomiting on elderly lung cancer patients, Methods This study was performed as a randomized climcal control trial. Seventy-one elderly lung cancer patients administered Pt.containing chemotherapy were included in the clinical trail.Results There was no significant difference in CRR during acute phase and delayed phase between treatment group and control group （P〉0.05）. The CRR of total phase （0 ~ 120 h post chemotherapy） was significantly higher in treatment group than that of control group（P〈0.05）. Conclusion The therapy of palonosetron plus dexamethasone is effective and safe for preventing both acute and delayed nausea and vomiting in patients with highly emetogenic chemotherapy, which is superior to tropisetron.

关 键 词：抗肿瘤含铂化疗方案 恶心呕吐 5-HT3 帕洛诺司琼 托烷司琼 老年 

分 类 号：R734.2[医药卫生—肿瘤]